呈交日期: 2025年9月2日 I. 法定/註冊股本變動 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海醫藥集團股份有限公司 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02607 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | | 2. 股份分類 | 普通股 | 股份類別 | A ...

Group 1: Overall Market Outlook - The report from Guojin Securities indicates an improvement in the performance of certain sectors such as ophthalmology, dentistry, and pharmacies in the first half of 2025, with a gradual decrease in performance pressure throughout 2024 [1][2] - The overall performance of traditional Chinese medicine companies is expected to improve as inventory continues to be digested and the execution time for centralized procurement of traditional Chinese medicine has been announced in multiple regions [1][2] Group 2: Traditional Chinese Medicine - In the first half of 2025, the overall performance of traditional Chinese medicine is under pressure, with both revenue and net profit being affected by lower flu incidence and inventory digestion [2] - The centralized procurement process is ongoing, but the execution progress has been slow, limiting the volume of selected products in hospitals [2] Group 3: Pharmacy Sector - The pharmacy sector experienced slight revenue pressure in the first half of 2025, although profits showed some recovery due to cost reduction and efficiency improvements [3] - The industry is undergoing consolidation, with a focus on compliance and the elimination of non-compliant stores, which may enhance market share for leading companies [3] Group 4: Medical Services and Consumer Healthcare - The medical services sector is recovering due to increased consumer demand and successful technological upgrades, with profit growth outpacing revenue growth [4] - Specific segments like ophthalmology and orthodontics are showing significant recovery, while serious medical fields face challenges due to payment reforms and cost control policies [4] - The application of AI technology is enhancing operational efficiency and accelerating business turnover, presenting opportunities for traditional medical services [4]

证券代码：601607 证券简称：上海医药 编号：临2025-080 上海医药集团股份有限公司 关于盐酸维拉帕米注射液通过仿制药一致性评价的公告 注册分类：化学药品 申请人：上海禾丰制药有限公司 药品批准文号：国药准字H31021343 审批结论：本品通过仿制药质量和疗效一致性评价。 二、该药品相关的信息 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海禾丰制药有限公司（以下简称"上药禾 丰"）的盐酸维拉帕米注射液（以下简称"该药品"）收到国家药品监督管理局（以下简称"国家药监 局"）颁发的《药品补充申请批准通知书》（通知书编号：2025B03892），该药品通过仿制药质量和疗 效一致性评价。 一、该药品基本情况 药品名称：盐酸维拉帕米注射液 剂型：注射剂 规格：2ml:5mg 根据国家相关政策，通过一致性评价的品种在医保支付及医疗机构采购等领域将获得更大的支持力度。 因此上药禾丰的盐酸维拉帕米注射液通过仿制药一致性评价，有利于扩大该药品的市场份额，提升市场 竞争 ...

Group 1 - Shanghai Pharmaceutical Group Co., Ltd. announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the consistency evaluation of the quality and efficacy of Verapamil Hydrochloride Injection [1][2] - The drug is primarily used for the rapid conversion of paroxysmal supraventricular tachycardia and for temporary control of ventricular rate in atrial flutter or atrial fibrillation [1][2] - The company has invested approximately RMB 3.29 million in research and development for this drug's consistency evaluation [1] Group 2 - As of the announcement date, there is one other company, Sichuan Meida Kangjiale Pharmaceutical Co., Ltd., that has also been deemed to have passed the consistency evaluation for this drug in China [2] - The IQVIA database indicates that the total procurement amount for Verapamil Hydrochloride Injection in hospitals in mainland China for 2024 is RMB 148.51 million [2] - The approval for consistency evaluation is expected to enhance the market share and competitiveness of Shanghai Hefeng's Verapamil Hydrochloride Injection, while also providing valuable experience for future product evaluations [2]

证券日报网讯 9月1日晚间，上海医药发布公告称，近日，公司下属上海禾丰制药有限公司的盐酸维拉 帕米注射液（简称"该药品"）收到国家药品监督管理局颁发的《药品补充申请批准通知书》，该药品通 过仿制药质量和疗效一致性评价。 （编辑 任世碧） ...

Group 1 - The core point of the article is that Shanghai Pharmaceuticals announced the approval of its Verapamil Hydrochloride Injection by the National Medical Products Administration, indicating that the drug has passed the consistency evaluation of quality and efficacy for generic drugs [3]. - The Verapamil Hydrochloride Injection is primarily used for the rapid conversion of paroxysmal supraventricular tachycardia and for the temporary control of ventricular rate in atrial flutter or atrial fibrillation [1].

盐酸维拉帕米注射液主要用于：1．快速阵发性室上性心动过速的转复。应用维拉帕米之前应首选抑制 迷走神经的手法治疗(如 Valsalva 法)。2．心房扑动或心房颤动心室率的暂时控制。心房扑动或心房颤 动合并房室旁路通道(预激综合症和 LGL 综合症)时除外。 格隆汇9月1日丨上海医药(02607.HK)发布公告，近日，公司下属上海禾丰制药有限公司(以下简称"上药 禾丰")的盐酸维拉帕米注射液收到国家药品监督管理局颁发的《药品补充申请批准通知书》(通知书编 号：2025B03892)，该药品通过仿制药质量和疗效一致性评价。 ...

Core Viewpoint - Shanghai Pharmaceuticals (02607) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its Verapamil Hydrochloride Injection, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The Verapamil Hydrochloride Injection is primarily used for the rapid conversion of paroxysmal supraventricular tachycardia and for temporary control of ventricular rate in atrial flutter or atrial fibrillation [1] - The company submitted a supplementary application for the consistency evaluation of this drug to the National Medical Products Administration in April 2024, which has been accepted [1] - As of the date of the announcement, the company has invested approximately RMB 3.29 million in research and development costs for the consistency evaluation of this drug [1]

格隆汇9月1日丨上海医药(601607.SH)公布，下属上海禾丰制药有限公司（简称"上药禾丰"）的盐酸维 拉帕米注射液收到国家药品监督管理局颁发的《药品补充申请批准通知书》，该药品通过仿制药质量和 疗效一致性评价。盐酸维拉帕米注射液主要用于：1．快速阵发性室上性心动过速的转复。应用维拉帕 米之前应首选抑制迷走神经的手法治疗（如Valsalva法）。2．心房扑动或心房颤动心室率的暂时控制。 心房扑动或心房颤动合并房室旁路通道（预激综合症和LGL综合症）时除外。 ...

（於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於鹽酸維拉帕米注射液通過仿製藥一致性評價的公 告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 9 月 2 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简 ...